Company Overview
About Menten AI
Menten AI is a San Francisco-based AI drug discovery company — backed by Y Combinator (W20) with $4.15 million in total funding from Y Combinator, Khosla Ventures, Uncork Capital, Feld Ventures, Mana Ventures, Quain Investments, Society Health, and Volpini Ventures — developing peptide and protein therapeutics using machine learning and quantum computing to design novel cyclic peptide drug candidates for pharmaceutical licensing partnerships, completing a research collaboration with Bristol Myers Squibb in May 2024. Founded in 2018, Menten AI applies advanced AI algorithms for cyclic peptide optimization and protein structure design with a business model centered on licensing proprietary algorithms and drug candidates to pharma partners rather than developing therapeutics through full clinical development.
Business Model & Competitive Advantage
Menten AI's AI peptide design platform addresses the molecular optimization challenge in macrocyclic peptide drug discovery: cyclic peptides (peptides where the chain forms a ring structure rather than a linear sequence) have emerged as a promising drug modality that bridges small molecules (cell-permeable, bioavailable) and biologics (can engage large, flat protein-protein interaction surfaces undruggable by small molecules) — but their design is computationally difficult because the ring conformational space is exponentially larger than linear peptide space, and predicting which conformations will achieve target binding affinity and membrane permeability requires advanced computational methods. Menten AI's ML models (predicting cyclic peptide binding to target proteins, membrane permeability, metabolic stability, and pharmacokinetic properties) accelerate the design-make-test cycle for cyclic peptide drug discovery by predicting which candidates will succeed before expensive synthesis and testing.
Competitive Landscape 2025–2026
In 2025, Menten AI competes in the AI drug discovery, cyclic peptide therapeutics, and computational chemistry market with PepGen (cyclic peptide therapeutics, NASDAQ: PEPG, $300M raised), Aileron Therapeutics (stapled peptides, NASDAQ: ALRN), and Relay Therapeutics (NASDAQ: RLAY, computational drug design, $700M raised) for pharmaceutical partner AI-assisted cyclic peptide drug candidate licensing and computational design collaboration adoption. Khosla Ventures' and Uncork Capital's investments reflect deep-tech drug discovery conviction. The Bristol Myers Squibb collaboration (BMS is a top-5 global pharmaceutical company with $45B+ revenue) validates Menten AI's platform quality for industry-grade peptide design. Y Combinator W20 backing positions Menten AI within the computational biology and AI drug discovery investment community. The 2025 strategy focuses on advancing the pipeline of cyclic peptide candidates for oncology and infectious disease targets, building the quantum computing-enhanced conformational sampling for improved prediction accuracy, and expanding the pharma partnership model with additional top-20 pharmaceutical company collaborations.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Menten AI is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Menten AI with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Menten AI? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Menten AI Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Menten AI vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →